These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29862563)

  • 21. Cutaneous T-cell lymphomas. A review of the recent literature.
    Zackheim HS
    Arch Dermatol; 1981 May; 117(5):295-304. PubMed ID: 6971626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.
    Horna P; Moscinski LC; Sokol L; Shao H
    Cytometry B Clin Cytom; 2019 May; 96(3):234-241. PubMed ID: 30328260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
    Bosisio FM; Cerroni L
    Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miRNA in mycosis fungoides and skin inflammation.
    Persson JL
    APMIS; 2013 Nov; 121(11):1017-9. PubMed ID: 24106870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.
    Clark RA; Shackelton JB; Watanabe R; Calarese A; Yamanaka K; Campbell JJ; Teague JE; Kuo HP; Hijnen D; Kupper TS
    Blood; 2011 Feb; 117(6):1966-76. PubMed ID: 21148332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T-cell Lymphoma.
    Miyagaki T; Sugaya M; Oka T; Takahashi N; Kawaguchi M; Suga H; Fujita H; Yoshizaki A; Asano Y; Sato S
    Acta Derm Venereol; 2017 May; 97(5):586-592. PubMed ID: 28119994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
    Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
    J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
    Brender C; Nielsen M; Kaltoft K; Mikkelsen G; Zhang Q; Wasik M; Billestrup N; Odum N
    Blood; 2001 Feb; 97(4):1056-62. PubMed ID: 11159537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of Cutaneous T-Cell Lymphomas.
    Larocca CA; LeBoeuf NR
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):669-686. PubMed ID: 31229162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative analysis of the expression of cell adhesion molecules in cutaneous T-cell lymphomas (mycosis fungoides/Sézary syndrome) and inflammatory skin diseases].
    López-Lerma I; Estrach MT
    Actas Dermosifiliogr; 2010 Dec; 101(10):866-77. PubMed ID: 21159263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
    Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
    Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides.
    Mao X; Lillington D; Scarisbrick JJ; Mitchell T; Czepulkowski B; Russell-Jones R; Young B; Whittaker SJ
    Br J Dermatol; 2002 Sep; 147(3):464-75. PubMed ID: 12207585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular pathogenesis of mycosis fungoides and Sézary syndrome.
    Döbbeling U
    G Ital Dermatol Venereol; 2008 Dec; 143(6):385-94. PubMed ID: 19169211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
    Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
    Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new molecular paradigm in mycosis fungoides and Sézary syndrome.
    Elenitoba-Johnson KS; Wilcox R
    Semin Diagn Pathol; 2017 Jan; 34(1):15-21. PubMed ID: 28024703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.
    Scarisbrick JJ; Woolford AJ; Calonje E; Photiou A; Ferreira S; Orchard G; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2002 Mar; 118(3):493-9. PubMed ID: 11874489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias.
    Morgan SM; Hodges E; Mitchell TJ; Harris S; Whittaker SJ; Smith JL
    J Invest Dermatol; 2006 Aug; 126(8):1893-9. PubMed ID: 16741518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous T-cell lymphoma: a review.
    Winkler CF; Bunn PA
    Crit Rev Oncol Hematol; 1983; 1(1):49-92. PubMed ID: 6083835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current pathogenetic aspects of Sézary syndrome and mycosis fungoides].
    Dummer R; Willers J; Döbbeling U; Burg G
    Hautarzt; 2001 Mar; 52(3):189-92. PubMed ID: 11284062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.
    Krejsgaard T; Odum N; Geisler C; Wasik MA; Woetmann A
    Leukemia; 2012 Mar; 26(3):424-32. PubMed ID: 21904385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.